BACKGROUND: Hepatic artery chemoembolization (HACE) is a treatment option in the management of metastatic carcinoid. We reviewed our experience to identify potential factors that influence survival. METHODS: The records of 122 patients with metastatic carcinoid tumor undergoing HACE were reviewed. Log-rank analysis and Cox proportional hazards were applied to identify factors predictive of decreased survival. RESULTS: Median follow-up after HACE was 21.5 months. Complications occurred in 23% with periprocedural mortality of 5%. Radiographic tumor regression was seen in 82%, with stabilization of disease in 12%. Median duration of CT response was 19 months. Improvement in symptoms occurred in 92% for median duration of 13 months. HACE resulted in complete normalization of serum pancreastatin in 14%, with greater than 20% reduction in another 66%. Median overall survival was 33.3 months after HACE. Only pancreastatin level > or =5,000 pg/ml was associated with decreased survival by multivariate analysis. CONCLUSION: HACE offers symptom palliation and long-term survival in patients with incurable carcinoid metastases. Although safe, it should be approached cautiously in patients with significant tumor burden as evidenced by pancreastatin levels > or =5,000 pg/ml. We do not recommend whole-liver embolization in these patients but prefer a staged approach to each lobe of the liver.
BACKGROUND: Hepatic artery chemoembolization (HACE) is a treatment option in the management of metastatic carcinoid. We reviewed our experience to identify potential factors that influence survival. METHODS: The records of 122 patients with metastatic carcinoid tumor undergoing HACE were reviewed. Log-rank analysis and Cox proportional hazards were applied to identify factors predictive of decreased survival. RESULTS: Median follow-up after HACE was 21.5 months. Complications occurred in 23% with periprocedural mortality of 5%. Radiographic tumor regression was seen in 82%, with stabilization of disease in 12%. Median duration of CT response was 19 months. Improvement in symptoms occurred in 92% for median duration of 13 months. HACE resulted in complete normalization of serum pancreastatin in 14%, with greater than 20% reduction in another 66%. Median overall survival was 33.3 months after HACE. Only pancreastatin level > or =5,000 pg/ml was associated with decreased survival by multivariate analysis. CONCLUSION: HACE offers symptom palliation and long-term survival in patients with incurable carcinoid metastases. Although safe, it should be approached cautiously in patients with significant tumor burden as evidenced by pancreastatin levels > or =5,000 pg/ml. We do not recommend whole-liver embolization in these patients but prefer a staged approach to each lobe of the liver.
Authors: K T Brown; B Y Koh; L A Brody; G I Getrajdman; J Susman; Y Fong; L H Blumgart Journal: J Vasc Interv Radiol Date: 1999-04 Impact factor: 3.464
Authors: Sanjay Gupta; Marcella M Johnson; Ravi Murthy; Kamran Ahrar; Michael J Wallace; David C Madoff; Stephen E McRae; Marshall E Hicks; Sujaya Rao; Jean-Nicolas Vauthey; Jaffer A Ajani; James C Yao Journal: Cancer Date: 2005-10-15 Impact factor: 6.860
Authors: K A Yao; M S Talamonti; A Nemcek; P Angelos; H Chrisman; J Skarda; A B Benson; S Rao; R J Joehl Journal: Surgery Date: 2001-10 Impact factor: 3.982
Authors: J R Strosberg; J M Weber; J Choi; T L Campos; T L Valone; G Han; M J Schell; L K Kvols Journal: Ann Oncol Date: 2012-02-08 Impact factor: 32.976
Authors: Kimberly A Varker; Edward W Martin; Dori Klemanski; Bryan Palmer; Manisha H Shah; Mark Bloomston Journal: J Gastrointest Surg Date: 2007-09-25 Impact factor: 3.452
Authors: Scott K Sherman; Jessica E Maxwell; M Sue O'Dorisio; Thomas M O'Dorisio; James R Howe Journal: Ann Surg Oncol Date: 2014-04-22 Impact factor: 5.344
Authors: Jill K Onesti; Lawrence A Shirley; Neil D Saunders; Gail W Davidson; Mary E Dillhoff; Hooman Khabiri; Gregory E Guy; Joshua D Dowell; Carl R Schmidt; Manisha H Shah; Mark Bloomston Journal: J Gastrointest Surg Date: 2015-10-21 Impact factor: 3.452
Authors: Nancy Sharma; Boris G Naraev; Eric G Engelman; M Bridget Zimmerman; David L Bushnell; Thomas M OʼDorisio; M Sue OʼDorisio; Yusuf Menda; Jan Müller-Brand; James R Howe; Thorvardur R Halfdanarson Journal: Pancreas Date: 2017-02 Impact factor: 3.327
Authors: Anne Klibanski; Shlomo Melmed; David R Clemmons; Annamaria Colao; Regina S Cunningham; Mark E Molitch; Aaron I Vinik; Daphne T Adelman; Karen J P Liebert Journal: Pituitary Date: 2010-09 Impact factor: 4.107